FAM228B_A830093I24Rik Inhibitors
Chemical inhibitors of family with sequence similarity 228, member B can disrupt its function through the modulation of various signaling pathways that regulate its activity. Triciribine, for instance, targets the AKT signaling pathway, a crucial conduit for transmitting signals that control survival and growth within the cell. By inhibiting AKT, triciribine can dampen the downstream signaling that family with sequence similarity 228, member B may rely on for its functional activity. Similarly, LY294002 and Wortmannin, both phosphoinositide 3-kinase (PI3K) inhibitors, curtail the upstream activity that leads to AKT activation. This results in a decreased phosphorylation and subsequent activation of AKT, thereby attenuating the signals towards family with sequence similarity 228, member B.
Complementing these AKT pathway inhibitors, Rapamycin operates on the mTOR complex, another downstream effector of AKT. By binding to FKBP12 and inhibiting the mTOR complex, Rapamycin can suppress the regulatory effects that mTOR exerts on various proteins, including family with sequence similarity 228, member B. Additionally, Palbociclib's inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) can lead to a cessation of cell cycle progression, which may impact the activity of proteins like family with sequence similarity 228, member B that are involved in cell cycle control. Moreover, MAPK pathway inhibitors, such as PD98059 and U0126, which target MEK, and SB203580 and SP600125, which target p38 MAPK and JNK respectively, can alter the signaling context within the cell, potentially influencing the functional state of family with sequence similarity 228, member B. Lastly, Dasatinib's inhibition of SRC family kinases and the more selective mTOR inhibitor PP242, as well as ZSTK474, a PI3K inhibitor, can disrupt the signaling milieu that family with sequence similarity 228, member B operates within, thus modulating its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine inhibits the AKT signaling pathway, which is known to regulate various cellular processes including metabolism, growth, and survival. Inhibition of AKT signaling by triciribine can lead to decreased function of downstream proteins such as family with sequence similarity 228, member B, which may be regulated by this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream regulators of the AKT pathway. Inhibiting PI3K activity with LY294002 would reduce AKT phosphorylation and activity, potentially leading to reduced activity of downstream targets including family with sequence similarity 228, member B. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that impedes the PI3K/AKT pathway. By inhibiting PI3K, wortmannin would diminish the signaling that may be necessary for the proper function of family with sequence similarity 228, member B. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and together they inhibit mTOR, which is a downstream target of the AKT pathway. Inhibition of mTOR by rapamycin could lead to a reduction in the functional activity of proteins such as family with sequence similarity 228, member B if they are downstream of mTOR signaling. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) which are involved in cell cycle progression. Inhibition of these kinases can lead to cell cycle arrest, which might inhibit the activity of proteins involved in cell cycle regulation such as family with sequence similarity 228, member B. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, which is part of the MAPK/ERK pathway. This pathway can interact with the PI3K/AKT pathway, and inhibition of MEK could lead to reduced activity of downstream proteins including family with sequence similarity 228, member B. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, a protein kinase involved in stress and inflammatory responses. Inhibition of p38 MAPK could indirectly inhibit the functional activity of family with sequence similarity 228, member B if it is involved in pathways regulated by p38 MAPK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), part of the MAPK signaling pathways. Inhibition of JNK could disrupt signaling pathways that regulate proteins such as family with sequence similarity 228, member B. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a BCR-ABL kinase inhibitor that also has inhibitory effects on SRC family kinases. As SRC kinases can interact with multiple signaling pathways, inhibition by dasatinib could lead to a reduction in the functional activity of proteins regulated by these pathways, including family with sequence similarity 228, member B. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, affecting the MAPK/ERK pathway. By inhibiting this pathway, U0126 could reduce the functional activity of downstream proteins such as family with sequence similarity 228, member B. | ||||||